AstraZeneca PLC
LSE:AZN
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
UK |
AstraZeneca PLC
LSE:AZN
|
185.8B GBP | 225.4 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
696.4B USD | 68.9 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 37.7 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 17 702.3 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 4 320.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
351.8B USD | 15.3 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.2B USD | 88.2 | ||
CH |
Novartis AG
SIX:NOVN
|
182.9B CHF | 16.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
176.2B CHF | 10 | ||
US |
Pfizer Inc
NYSE:PFE
|
143.4B USD | 15.3 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.